India: Xtandi Patent Fight May Delay Entry Of Essential Drugs At Affordable Prices

Last Updated: 8 August 2017
Article by Vijaylaxmi Rathore

Most Read Contributor in India, July 2017

The Indian pharmaceuticals with its proven product standards and national and International regulatory compliance is the 3rd largest producer and suppliers of cost-effective generic medicines worldwide. The effort to make affordable lifesaving drugs availability for the general population is a huge task performed only if pharmaceutical firms and regulatory authorities go along. In India, the affordability of drugs is monitored and regulated by National Pharmaceutical Pricing Authority (NPPA), a regulatory agency under Department of Pharmaceuticals. NPPA plays a major role in bringing down the prices of essential lifesaving medicines in the country. As a result, the lifesaving drugs are available in India at a more reasonable and economical price compared to other countries. Moreover, the Indian Patents Office (IPO), while being dedicated towards the innovation support by grant and protection of patents, also allows for certain exclusions to monopoly especially with respect to innovations in pharmaceutical sector. Here we are discussing the measures taken by IPO and NPPA towards drugs affordability in India.

National Pharmaceutical Pricing Authority (NPPA):

NPPA is a regulatory and executive agency to implement Drug Price Control Order (DPCO), 1913, under Essential Commodities Act, 1955. The NPPA regulates the price of schedule-I drugs, thereby list of essential medicines updated by regulators time to time. The NPPA fix the maximum ceiling price of Schedule-I drugs and publish through National List of Essential Medicines (NELM) periodically. Moreover, apart from the price control of scheduled drugs, the certain provisions of DPCO are specifically to monitor the price of non-scheduled drugs.

Non-scheduled drugs and NPPA: The NPPA's right to control the prices of non-scheduled drugs (drugs not listed in schedule-I) is performed under Para 19 of DPCO, 2013. Likewise, the NPPA monitors the price of non-scheduled drugs under Para 20 of DPCO, 2013, as explains below-

  • Paragraph 19 of DPCO prescribes that, notwithstanding anything contained in this order, the Government may, in case of extra-ordinary circumstances, if it considers necessary so to do in public interest, fix the ceiling price or retail price of any drug for such period, as it may deem fit and where the ceiling price or retail price of the drug is already fixed and notified, the Government may allow an increase or decrease in the ceiling price or the retail price, as the case may be, irrespective of annual wholesale price index for that year.

Note- the internal guidelines of Para 19 of the DPCO, 2013 was withdrawn by immediate effect on 19.09.2014 vide letter no. 31026/ 53/ 2014-PI-II12. However, Department of Pharmaceuticals (DoP) has formed a new inter-ministerial committee and instigated them to examine and frame a method that targeted to bring down the exorbitant price of patented drugs within the country either by negotiation or reference pricing13.

  • Paragraph 20 of DPCO, 2013: Monitoring the prices of non-scheduled formulations-
  1. The Government shall monitor the maximum retail prices (MRP) of all the drugs, including the non-scheduled formulations and ensure that no manufacturer increases the maximum retail price of a drug more than ten percent of maximum retail price during preceding twelve months and where the increase is beyond ten percent of maximum retail price, it shall reduce the same to the level of ten percent of maximum retail price for next twelve months.
  2. The manufacturer shall be liable to deposit the overcharged amount along with interest thereon from the date of increase in price in addition to the penalty.

Patented Drugs and NPPA: The non-applicability of the provisions of DPCO is being prescribed under Para 32 of DPCO, 2013.

  • Paragraph 32 of DPCO, 2013: Stipulates that the provisions of DPCO shall not apply to certain cases :
  1. A manufacturer producing a new drug patented under the Indian Patents Act, 1970, (product patent) and not produced elsewhere, if developed through indigenous Research and Development, for a period of five years from the date of commencement of its commercial production in the country.
  2. A manufacturer producing a new drug in the country by a new process developed through indigenous Research and Development and patented under the Indian Patents Act, 1970 (process patent) for a period of five years from the date of the commencement of its commercial production in the country.
  3. A manufacturer producing a new drug involving a new delivery system developed through indigenous Research and Development for a period of five years from the date of its market approval in India.

Provided that the provisions of the above paragraph shall be applicable only when a document showing the approval of such "new drugs" by the Drugs Controller General of India (DCGI) is produced before the Government.

The Indian Patents Act (IPA):

There are certain provisions of the IPA, which play a major role in pharmaceutical related invention, and its affordability and availability. Sections such as Section 3(d) and Section 3(e) are important with respect to pharmaceutical inventions, and Section 84(1b) and 92(1) encapsulates for drug affordability and availability respectively under special circumstances.

Section 3(d) and 3(e) narrows down the scope of patentability for insignificant or incremental pharmaceutical discoveries and supports the true innovations in terms of efficacy.

  • Section 3(d) prescribes that the mere discovery of a new form of a known substance which does not result in enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant is not patentable.
  • Section 3 (e) prescribes that a substance obtained by a mere admixture resulting only in the aggregation of the properties of the components thereof or a process for producing such substance is not patentable.

The Section 84(1) relates to compulsory licensing provisions under IPA, whereby, the Controller of Patents is empowered to grant compulsory licenses after expiration of three year from the date of the grant of the patent under prescribed grounds-

  1. That the reasonable requirements of the public with respect to the patented invention have not been satisfied, or
  2. That the patented invention is not available to the public at a reasonably affordable price, or
  3. That the patented invention is not worked in the territory of India.

It is to be noted that the clause (b) above mandates the patentee make the patented drug available to the public at a reasonably affordable price, so as to avoid the said patent from being considered for compulsory licensing.

Further, Section 92(1) prescribes that if the central government is satisfied that in circumstances of national emergency or in extreme urgency or in case of public non-commercial use, it is necessary that the compulsory license should be granted to work the patent, it may make a declaration to that effect by notification in the official gazette, whereupon-

  1. The Controller shall on application made at any time after the notification by any person interested grant to the applicant a license under the patent on such terms and conditions as he thinks fit;
  2. In settling the terms and conditions of license granted under this section, the Controller shall endeavor to secure that the articles manufactured under the patent shall be available to the public at the lowest prices consistent with the patentees deriving a reasonable advantage from their patent rights.

Accordingly, in case of said extreme circumstances and upon Gazette notification by the Central Government the Controller is empowered to grant compulsory licenses with respect to the notified patents and while doing so the Controller is required under aforementioned provision (ii) to make the patent available to the public at lowest prices consistent with the patentees deriving a reasonable advantage from their patent rights.

Upon considering the provisions of the NPPA and IPA, it can be said that the affordability and availability of pharmaceuticals is directly and/or indirectly affected by DPCO, 2013 and Indian patent system, which is to the benefit of public at large in India. However, it has been seem at some instances that the said systems create a hurdle in pharmaceutical growth and expansion in the country, since the pharmaceutical companies do become indecisive with respect to launching of their products in India as compare to U.S. and European countries.

Xtandi Vs Indian Patent Office:

Xtandi (generic name-Enzalutamide), a synthetic non-steroidal, anti-androgen drug developed by a group of researchers from University of California, Los Angeles (UCLA), who then licensed its patents to a US based biopharmaceutical company called Medivation. Later in 2009, Medivation in a joint venture with Astellas, a Japanese

pharmaceutical company started developing, marketing and commercializing Enzalutamide globally14. In August 2012, USFDA approved MDV3100 (Enzalutamide) for the treatment of metastatic castration-resistant prostate cancer. At present apart from Medivation and astellas, Pfizer also got the right over Xtandi as a result of medivation acquisitions in 201615.

Xtandi is a potent, best-seller but also a high-priced anticancer medicine by Astellas for the treatment of the second most common cancer in men. Despite the claims of providing coupons, Medicare and some patient assistance programs to uninsured or underinsured cancer patients by Astellas 16. The Drug still appears costly especially for economically disadvantaged African-Americans in U.S., as Xtandi price is much higher costing around $129,000 in a year in USA than the other high income countries. As a result, the US congress and lawmakers are demanding an open and transparent public hearing on Xtandi pricing; and the major concern of demand is the exorbitant pricing of Xtandi in USA despite its being developed in their own country by using their own funds17.

In India, Astellas is selling Xtandi at the estimated cost of $45 for each 40 mg pill and $179 (Rs. 11521.33) per day, a way expensive then the daily income of a person in India (As per the World Bank report 2015, the estimated daily income of a person in India is $4.36 (Rs. 280.00)). However, these

exorbitant pricing and ongoing patent fight for Xtandi has been opposed at various level. For e.g. the Union for Affordable Cancer Treatment (UACT) together with 56 organizations has requested the reagent of University of California, Los Angeles (UCLA) to back off its petition filed to Delhi high court against the IPO decision of patent denial. As this ongoing patent fight may delay the generic version of Enzalutamide (Xtandi) in the country; and its supply to other low economic countries where the said drug has no patents and/or not affordable anyway18.

Unfortunately, It's been a decade for Xtandi patent fight in India, the UCLA application for Xtandi patent was first filed at Indian Patent Office (IPO), Delhi in 2007 (Application Number – 9668/DELNP/2007). Thereupon, Indian Pharmaceutical Alliance, Fresenius kabi, BDR Pharma and few individuals filed opposition against this application on 2012, 2013 and so on. Later in 2016, the IPO rejected the application on the grounds of; lack of inventiveness, section 3(d) and Section 3 (e) of the Patents Act. Consequently the reagent of UCLA filed a petition before the Delhi high Court challenging the IPO decision of patent refusal and looking forward for the next hearing.

CONCLUSION

Xtandi will either win the patent fight or not, but in both the situations it will have a vital impact on the affordability of said drugs amongst the cancer patients in India. The ongoing fight for patent is already a reason for delay in availability of the generic version of Enzalutamide (Xtandi) for the cancer patients in India.

If Xtandi does not receive the patent protection-

  • The Pharmaceutical industries in India may manufacture the generic version of Enzalutamide on the grounds of no patent, and
  • The provision to bring down the price of non-scheduled formulations under paragraph 19 and 20 of DPCO, 2013 will be also applicable.

If Xtandi receives the patent protection- The Indian government will have two options to bring down Xtandi's price:

  • The provision to grant compulsory license after expiration of three year from the date of the grant of the patent based on aforementioned circumstances under Section 84(1) and Section 92(1), will be applicable.
  • The provision to bring down the price of non-scheduled formulations under paragraph 19 and 20 of DPCO, 2013 will might be applicable. As Xtandi has not developed through indigenous/ domestic R&D process would be out of the Paragraph 32 exclusion as stated above.

Footnotes

12 http://www.dpco2013.com/files/data/pricefixationunderpara19/20331472541493.pdf

13 http://pharmaceuticals.gov.in/sites/default/files/CommitteePatentedDrugs_0.pdf 

14 http://files.shareholder.com/downloads/MDV/1855075331x0x326521/3a8e7d97-2e58-43fd-8e13-f0022dcf224d/MDVN_News_2009_10_27_General_Releases.pdf

15 http://www.latimes.com/business/la-fi-pfizer-medivation-acquisition-20160822-snap-story.html

16 https://www.keionline.org/node/2485

17 http://www.fiercepharma.com/regulatory/updated-astellas-cancer-med-xtandi-draws-fire-as-u-s-lawmakers-demand-a-pricing-hearing

18 https://cancerunion.org/2017/05/24/uact-55-others-ask-university-of-california-to-drop-appeal-of-prostate-cancer-patent-in-india/

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.